Search General Info
Search Education
Search Partnering Companies
Genesis Therapeutics
4:15 PM - 4:30 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104C
![BIO International Convention](/sites/default/files/2021-09/_BIO_CONV_Logo-White.png)
Genesis Therapeutics has created the industry's most advanced molecular AI platform by combining physics-aware deep neural networks, new molecular simulation methods, and a massively scalable molecular generation engine. The company’s small molecule AI platform is uniquely able to address previously undruggable and data-poor targets, enabling immense swaths of chemical space to be searched.
Genesis is building an internal pipeline in oncology, and currently has 4 preclinical programs against high value targets. Genesis additionally announced a $20M upfront, $670M deal with Eli Lilly in April 2022 (for collaboration on three initial targets; Lilly has the option to nominate two more targets for an additional nomination payment per target). Genesis also has a discovery collaboration with Genentech (started in 2020), and raised a $52M Series A in 2020 with top tier investors including a16z, Rock Springs and T Rowe Price.
Genesis is building an internal pipeline in oncology, and currently has 4 preclinical programs against high value targets. Genesis additionally announced a $20M upfront, $670M deal with Eli Lilly in April 2022 (for collaboration on three initial targets; Lilly has the option to nominate two more targets for an additional nomination payment per target). Genesis also has a discovery collaboration with Genentech (started in 2020), and raised a $52M Series A in 2020 with top tier investors including a16z, Rock Springs and T Rowe Price.
![](https://www.abstractscorecard.com/uploads/Tasks/upload/20525/EOISBJNL-1528507-1-JPG.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Preclinical small molecule targeted oncology program (solid tumors, recently declared development candidate).
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
![](https://www.conferenceharvester.com/uploads/harvester/photos/EOISBJNL-Presenter-TilburyC.jpg)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved